Will Merck's COVID-19 Pill Sink Regeneron's and Eli Lilly's Antibody Therapy Sales?

Will Merck's COVID-19 Pill Sink Regeneron's and Eli Lilly's Antibody Therapy Sales?

Submitted by admin on October 22, 2021 - 12:18pm
Source: 
Motley Fool
News Tags: 
Merck
COVID-19
molnupiravir
Regeneron
Eli Lilly
antibodies
Headline: 
Will Merck's COVID-19 Pill Sink Regeneron's and Eli Lilly's Antibody Therapy Sales?
snippet: 
  • Merck's COVID-19 pill will be much more convenient for patients than current antibody therapies.
  • Regeneron's and Lilly's COVID-19 antibody therapy sales will likely fall once Merck's pill reaches the market.
  • The key limiting factor for Merck will be how many pills it can produce.

Do Not Allow Advertisers to Use My Personal information